Medicare Launches GLP-1 Bridge Program to Cut Weight Loss Drug Costs for Seniors

The Centers for Medicare and Medicaid Services launched the "GLP-1 Bridge" pilot program in July 2026, giving eligible Medicare Part D beneficiaries access to approved weight loss medications for a flat $50 monthly copayment.

The program covers oral and injectable versions of Wegovy, Zepbound, and Foundayo, the first once-daily oral GLP-1 pill approved by the FDA in April 2026. It runs through December 2027 and bypasses traditional Part D plan structures through a prior authorization system.

The launch comes as GLP-1 medications have become some of the most prescribed drugs in the country. Novo Nordisk's oral version of Wegovy launched in the United States on January 5, 2026, and saw about 170,000 prescriptions written in its first three weeks.

Affordability has been a major barrier. Without insurance coverage, GLP-1 medications can cost hundreds of dollars per month. The Bridge program is designed to help patients who previously faced high out-of-pocket expenses.

Researchers have also expanded their understanding of how these drugs work. Studies show that oral small-molecule GLP-1 drugs can penetrate the brain to modulate reward circuits, suppressing eating for pleasure. Separate research found that patients who switched from weekly injectable GLP-1s to daily oral versions maintained about 75 to 80 percent of their previous weight loss.

Concerns remain about counterfeit pills and compounded versions of GLP-1 medications, which have been linked to hundreds of adverse event reports. Authorities have warned patients to obtain these drugs only through licensed pharmacies with valid prescriptions.